Search results
Results from the WOW.Com Content Network
Mifepristone, and also known by its developmental code name RU-486, is a drug typically used in combination with misoprostol to bring about a medical abortion during pregnancy. [8] This combination is 97% effective [ 9 ] during the first 63 days (9 weeks) of pregnancy , yet effective in the second trimester as well.
Toggle History subsection. 5.1 Prevalence. ... In 1981, French pharmaceutical company Roussel-Uclaf developed the antiprogestogen mifepristone (also known as RU-486).
Anthony Comstock was ultimately responsible for many anti-contraception laws in the U.S.. Contraception was not restricted by law in the United States throughout most of the 19th century, but in the 1870s a social purity movement grew in strength, aimed at outlawing vice in general, and prostitution and obscenity in particular. [22]
Language links are at the top of the page. Search. Search
Misoprostol is most effective when it is used in combination with methotrexate or mifepristone (RU-486). [35] Mifepristone blocks signaling by progesterone , causing the uterine lining to degrade, the blood vessels of the cervix and uterus to dilate and causing uterine contraction, similar to a menstrual period , which causes the embryo to ...
Antiprogestogens or antiprogestins, also known as progesterone antagonists or progesterone blockers, are a class of drugs which prevent progestogens like progesterone from mediating their biological effects in the body.
1988 – France legalized the "abortion pill" mifepristone (RU-486). 1988 – In R. v. Morgentaler , the Supreme Court of Canada struck down an abortion regulation which allowed abortions in some circumstances but required approval of a committee of doctors for violating a woman's constitutional " security of person "; Canadian law has not ...
Roussel Uclaf S.A. was a French pharmaceutical company and one of several predecessor companies of today's Sanofi. It was the second largest French pharmaceutical company [6] before it was acquired by Hoechst AG of Frankfurt, Germany in 1997, with pharmaceutical operations combined into the Hoechst Marion Roussel (HMR) division in the United States.